Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders

An Analysis of Secondary Measures

David J. Posey, Michael G. Aman, James T. McCracken, Lawrence Scahill, Elaine Tierney, L. Eugene Arnold, Benedetto Vitiello, Shirley Z. Chuang, Mark Davies, Yaser Ramadan, Andrea N. Witwer, Naomi Swiezy, Pegeen Cronin, Bhavik Shah, Deirdre H. Carroll, Christopher Young, Courtney Wheeler, Christopher J. McDougle

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Methylphenidate has been shown elsewhere to improve hyperactivity in about half of treated children who have pervasive developmental disorders (PDD) and significant hyperactive-inattentive symptoms. We present secondary analyses to better define the scope of effects of methylphenidate on symptoms that define attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD), as well as the core autistic symptom domain of repetitive behavior. Methods: Sixty-six children (mean age 7.5 y) with autistic disorder, Asperger's disorder, and PDD not otherwise specified, were randomized to varying sequences of placebo and three different doses of methylphenidate during a 4-week blinded, crossover study. Methylphenidate doses used approximated .125, .25, and .5 mg/kg per dose, twice daily, with an additional half-dose in the late afternoon. Outcome measures included the Swanson, Nolan, and Pelham Questionnaire revised for DSM-IV (ADHD and ODD scales) and the Children's Yale-Brown Obsessive Compulsive Scales for PDD. Results: Methylphenidate was associated with significant improvement that was most evident at the .25- and .5-mg/kg doses. Hyperactivity and impulsivity improved more than inattention. There were not significant effects on ODD or stereotyped and repetitive behavior. Conclusions: Convergent evidence from different assessments and raters confirms methylphenidate's efficacy in relieving ADHD symptoms in some children with PDD. Optimal dose analyses suggested significant interindividual variability in dose response.

Original languageEnglish
Pages (from-to)538-544
Number of pages7
JournalBiological Psychiatry
Volume61
Issue number4
DOIs
StatePublished - Feb 15 2007

Fingerprint

Methylphenidate
Attention Deficit and Disruptive Behavior Disorders
Attention Deficit Disorder with Hyperactivity
Asperger Syndrome
Stereotyped Behavior
Impulsive Behavior
Autistic Disorder
Diagnostic and Statistical Manual of Mental Disorders
Cross-Over Studies
Placebos
Outcome Assessment (Health Care)

Keywords

  • Asperger's disorder
  • autism
  • hyperactivity
  • inattention
  • methylphenidate
  • pervasive developmental disorder
  • stimulants

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders : An Analysis of Secondary Measures. / Posey, David J.; Aman, Michael G.; McCracken, James T.; Scahill, Lawrence; Tierney, Elaine; Arnold, L. Eugene; Vitiello, Benedetto; Chuang, Shirley Z.; Davies, Mark; Ramadan, Yaser; Witwer, Andrea N.; Swiezy, Naomi; Cronin, Pegeen; Shah, Bhavik; Carroll, Deirdre H.; Young, Christopher; Wheeler, Courtney; McDougle, Christopher J.

In: Biological Psychiatry, Vol. 61, No. 4, 15.02.2007, p. 538-544.

Research output: Contribution to journalArticle

Posey, DJ, Aman, MG, McCracken, JT, Scahill, L, Tierney, E, Arnold, LE, Vitiello, B, Chuang, SZ, Davies, M, Ramadan, Y, Witwer, AN, Swiezy, N, Cronin, P, Shah, B, Carroll, DH, Young, C, Wheeler, C & McDougle, CJ 2007, 'Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders: An Analysis of Secondary Measures', Biological Psychiatry, vol. 61, no. 4, pp. 538-544. https://doi.org/10.1016/j.biopsych.2006.09.028
Posey, David J. ; Aman, Michael G. ; McCracken, James T. ; Scahill, Lawrence ; Tierney, Elaine ; Arnold, L. Eugene ; Vitiello, Benedetto ; Chuang, Shirley Z. ; Davies, Mark ; Ramadan, Yaser ; Witwer, Andrea N. ; Swiezy, Naomi ; Cronin, Pegeen ; Shah, Bhavik ; Carroll, Deirdre H. ; Young, Christopher ; Wheeler, Courtney ; McDougle, Christopher J. / Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders : An Analysis of Secondary Measures. In: Biological Psychiatry. 2007 ; Vol. 61, No. 4. pp. 538-544.
@article{77a19df6399d4b1c8eeb2eae67145cb2,
title = "Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders: An Analysis of Secondary Measures",
abstract = "Background: Methylphenidate has been shown elsewhere to improve hyperactivity in about half of treated children who have pervasive developmental disorders (PDD) and significant hyperactive-inattentive symptoms. We present secondary analyses to better define the scope of effects of methylphenidate on symptoms that define attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD), as well as the core autistic symptom domain of repetitive behavior. Methods: Sixty-six children (mean age 7.5 y) with autistic disorder, Asperger's disorder, and PDD not otherwise specified, were randomized to varying sequences of placebo and three different doses of methylphenidate during a 4-week blinded, crossover study. Methylphenidate doses used approximated .125, .25, and .5 mg/kg per dose, twice daily, with an additional half-dose in the late afternoon. Outcome measures included the Swanson, Nolan, and Pelham Questionnaire revised for DSM-IV (ADHD and ODD scales) and the Children's Yale-Brown Obsessive Compulsive Scales for PDD. Results: Methylphenidate was associated with significant improvement that was most evident at the .25- and .5-mg/kg doses. Hyperactivity and impulsivity improved more than inattention. There were not significant effects on ODD or stereotyped and repetitive behavior. Conclusions: Convergent evidence from different assessments and raters confirms methylphenidate's efficacy in relieving ADHD symptoms in some children with PDD. Optimal dose analyses suggested significant interindividual variability in dose response.",
keywords = "Asperger's disorder, autism, hyperactivity, inattention, methylphenidate, pervasive developmental disorder, stimulants",
author = "Posey, {David J.} and Aman, {Michael G.} and McCracken, {James T.} and Lawrence Scahill and Elaine Tierney and Arnold, {L. Eugene} and Benedetto Vitiello and Chuang, {Shirley Z.} and Mark Davies and Yaser Ramadan and Witwer, {Andrea N.} and Naomi Swiezy and Pegeen Cronin and Bhavik Shah and Carroll, {Deirdre H.} and Christopher Young and Courtney Wheeler and McDougle, {Christopher J.}",
year = "2007",
month = "2",
day = "15",
doi = "10.1016/j.biopsych.2006.09.028",
language = "English",
volume = "61",
pages = "538--544",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders

T2 - An Analysis of Secondary Measures

AU - Posey, David J.

AU - Aman, Michael G.

AU - McCracken, James T.

AU - Scahill, Lawrence

AU - Tierney, Elaine

AU - Arnold, L. Eugene

AU - Vitiello, Benedetto

AU - Chuang, Shirley Z.

AU - Davies, Mark

AU - Ramadan, Yaser

AU - Witwer, Andrea N.

AU - Swiezy, Naomi

AU - Cronin, Pegeen

AU - Shah, Bhavik

AU - Carroll, Deirdre H.

AU - Young, Christopher

AU - Wheeler, Courtney

AU - McDougle, Christopher J.

PY - 2007/2/15

Y1 - 2007/2/15

N2 - Background: Methylphenidate has been shown elsewhere to improve hyperactivity in about half of treated children who have pervasive developmental disorders (PDD) and significant hyperactive-inattentive symptoms. We present secondary analyses to better define the scope of effects of methylphenidate on symptoms that define attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD), as well as the core autistic symptom domain of repetitive behavior. Methods: Sixty-six children (mean age 7.5 y) with autistic disorder, Asperger's disorder, and PDD not otherwise specified, were randomized to varying sequences of placebo and three different doses of methylphenidate during a 4-week blinded, crossover study. Methylphenidate doses used approximated .125, .25, and .5 mg/kg per dose, twice daily, with an additional half-dose in the late afternoon. Outcome measures included the Swanson, Nolan, and Pelham Questionnaire revised for DSM-IV (ADHD and ODD scales) and the Children's Yale-Brown Obsessive Compulsive Scales for PDD. Results: Methylphenidate was associated with significant improvement that was most evident at the .25- and .5-mg/kg doses. Hyperactivity and impulsivity improved more than inattention. There were not significant effects on ODD or stereotyped and repetitive behavior. Conclusions: Convergent evidence from different assessments and raters confirms methylphenidate's efficacy in relieving ADHD symptoms in some children with PDD. Optimal dose analyses suggested significant interindividual variability in dose response.

AB - Background: Methylphenidate has been shown elsewhere to improve hyperactivity in about half of treated children who have pervasive developmental disorders (PDD) and significant hyperactive-inattentive symptoms. We present secondary analyses to better define the scope of effects of methylphenidate on symptoms that define attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD), as well as the core autistic symptom domain of repetitive behavior. Methods: Sixty-six children (mean age 7.5 y) with autistic disorder, Asperger's disorder, and PDD not otherwise specified, were randomized to varying sequences of placebo and three different doses of methylphenidate during a 4-week blinded, crossover study. Methylphenidate doses used approximated .125, .25, and .5 mg/kg per dose, twice daily, with an additional half-dose in the late afternoon. Outcome measures included the Swanson, Nolan, and Pelham Questionnaire revised for DSM-IV (ADHD and ODD scales) and the Children's Yale-Brown Obsessive Compulsive Scales for PDD. Results: Methylphenidate was associated with significant improvement that was most evident at the .25- and .5-mg/kg doses. Hyperactivity and impulsivity improved more than inattention. There were not significant effects on ODD or stereotyped and repetitive behavior. Conclusions: Convergent evidence from different assessments and raters confirms methylphenidate's efficacy in relieving ADHD symptoms in some children with PDD. Optimal dose analyses suggested significant interindividual variability in dose response.

KW - Asperger's disorder

KW - autism

KW - hyperactivity

KW - inattention

KW - methylphenidate

KW - pervasive developmental disorder

KW - stimulants

UR - http://www.scopus.com/inward/record.url?scp=33846643952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846643952&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2006.09.028

DO - 10.1016/j.biopsych.2006.09.028

M3 - Article

VL - 61

SP - 538

EP - 544

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 4

ER -